Plymouth, MA – November 12, 2024 – MitoSense Inc., a leader in mitochondria lresearch and innovation, proudly announces the publication of its groundbreaking study in the Journal of Biomaterials and Nanobiotechnology. The research, titled “Cryopreserved Fibroblast and Mesenchymal Stem Cells (MSCs) as Alternative Mitochondrial Donors for Mitochondrial Organelle Transplantation (MOT),” highlights a significant advancement in the field of mitochondrial therapies for urgent medical conditions.
The study, led by MitoSense researchers in collaboration with James A. Haley VA Medical Center, demonstrates that mitochondria isolated from cryopreserved fibroblasts and MSCs maintain comparable viability and functional transferability to mitochondria derived from fresh cells. Notably, the research also found that MSCs, compared to fibroblasts, exhibited comparable ATP content and oxygen consumption rates (OCRs), making them excellent candidates for mitochondrial donation.
Mitochondrial Organelle Transplantation (MOT™) is an innovative therapeutic strategy that has shown potential in addressing neurodegenerative diseases including ALS, Parkinson's, Alzheimer's, and Traumatic Brain Injury (TBI). However, traditional mitochondria isolation methods relying on fresh cell expansion often face limitations in urgent clinical scenarios due to the time-intensive nature of cell preparation.
“This study marks a pivotal step forward in overcoming the challenges of cell preparation for urgent MOT,” said Van Hipp, Chairman of MitoSense Inc. “The ability to use cryopreserved fibroblasts and MSCs as alternative mitochondrial sources not only expands the practicality of MOT™ but also enhances its potential for rapid deployment in critical medical situations.”
The findings open new pathways for utilizing centralized cGMP-compliant facilities to bank and distribute cryopreserved cells, allowing for seamless and timely mitochondrial transplants at clinical sites equipped with advanced processing systems.
The research team extends sincere gratitude to the James A. Haley VA Medical Center and its dedicated staff for their invaluable partnership and support, underscoring the importance of collaborative efforts in advancing medical innovation.
About MitoSense Inc.
MitoSense Inc. is at the forefront of mitochondrial research, committed to developing pioneering solutions that harness the potential of mitochondria to transform treatments for various medical conditions.
For further information about MitoSense and its research efforts, visit www.mitosense.com or contact the company at info@mitosense.com.